| abstract |
The present invention relates to methods for the treatment of cancer associated with WEE1 kinase, by administering a WEE1 inhibitor, wherein the WEE1 inhibitor is WEE1-1, or a pharmaceutically acceptable salt thereof, or WEE1-2, or a pharmaceutically acceptable salt thereof; In another embodiment, the invention relates to a method for treating a cancer patient associated with WEE1 kinase, which comprises administering a WEE1 inhibitor, wherein the cancer cells of said patient to be treated are characterized by low levels. of PKMYT1 expression. |